Pre- and post-exposure safety and efficacy of attenuated rabies virus vaccines are enhanced by their expression of IFNγ

Virology

Volumn 474, Issue , 2015, Pages 174-180

  Barkhouse, Darryll A ^a,c   Faber, Milosz ^b,c   Hooper, D Craig ^a,b,c  

^a Department of Cancer Biology ^*  (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Center for Neurovirology   (United States)

Author keywords

CNS; Interferon gamma; Post exposure treatment; Rabies; Vaccine

Indexed keywords

GAMMA INTERFERON; GASGAMMA VACCINE; GASGAS VACCINE; GASOGAS VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TYPE; COLONY FORMING UNIT; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; GASGAMMA VIRUS; GASGAMMAGAS VIRUS; GASGAS VIRUS; GASOGAS VIRUS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; SPBNGAMMA VIRUS; SUCKLING ANIMAL; SURVIVAL RATE; VACCINATION; VIROGENESIS; VIRUS GENOME; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; CELL LINE; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; MUTATION; PATHOGENICITY; VIRULENCE;

RABIES VIRUS;

ANIMALS; ANIMALS, SUCKLING; CELL LINE; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; GENOME, VIRAL; INTERFERON-GAMMA; MICE; MUTATION; RABIES; RABIES VACCINES; RABIES VIRUS; RECOMBINANT PROTEINS; VACCINES, ATTENUATED; VIRULENCE;

EID: 84911419042     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.10.025     Document Type: Article

References (35)

1. Badiane F.J. Modification of the Immune Response to Ovalbumin Expressed by a Rabies Virus Vector 2011, (Master's thesis), Thomas Jefferson University, Philadelphia, PA.
2. Baer G.M., Shaddock J.H., Williams L.W. Prolonging morbidity in rabid dogs by intrathecal injection of attenuated rabies vaccine. Infect. Immun. 1975, 12:98-103.
3. Barkhouse D.A., Garcia S.A., Bongiorno E.K., Lebrun A., Faber M., Hooper D.C. Expression of IFNγ by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon. J. Virol. 2014, (epub ahead of print) 10.1128/JVI.01572-14.
4. Conzelmann K.K., Cox J.H., Schneider L.G., Thiel H.J. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 1990, 175:485-499.
5. Dietzschold B., Morimoto K., Hooper D.C., Smith J.S., Rupprecht C.E., Koprowski H. Genotypic and phenotypic diversity of rabies virus variants involved in human rabies: implications for postexposure prophylaxis. J. Hum. Virol 2000, 3:50-57.
6. Faber M., Pulmanausahakul R., Hodawadekar S.S., Spitsin S., McGettigan J.P., Schnell M.J., Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 2002, 76:3374-3381.
7. Faber M., Faber M.-L., Papaneri A., Bette M., Weihe E., Dietzschold B., Schnell M.J. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J. Virol. 2005, 79:14141-14148.
8. Faber M., Bette M., Preuss M.A.R., Pulmanausahakul R., Rehnelt J., Schnell M.J., Dietzschold B., Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J. Virol. 2005, 79:15405-15416.
9. Faber M., Faber M-L., Li J., Preuss M.A.R., Schnell M.J., Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J. Virol. 2007, 81:7041-7047.
10. Faber M., Li J., Kean R.B., Hooper D.C., Alugupalli K.R., Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. U.S.A 2009, 106:11300-11305.
11. Franka R., Wu X., Jackson F.R., Velasco-Villa A., Palmer D.P., Henderson H., Hayat W., Green D.B., Blanton J.D., Greenberg L., Rupprecht C.E. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 2009, 27:7149-7155.
12. Giavedoni L., Ahmad S., Jones L., Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J. Virol. 1997, 71:866-872.
13. Gomez C.M., Maselli R., Gundeck J.E., Chao M., Day J.W., Tamamizu S., Lasalde J.A., McNamee M., Wollmann R.L. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J. Neurosci. 1997, 17:4170-4179.
14. Griffin D.E. Recovery from viral encephalomyelitis: immune-mediated noncytolytic virus clearance from neurons. Immunol. Res. 2010, 47:123-133.
15. Haq K., Elawadli I., Parvizi P., Mallick A.I., Behboudi S., Sharif S. Interferon-γ influences immunity elicited by vaccines against very virulent Marek's disease virus. Antivir. Res. 2011, 90:218-226.
16. Hooper D.C., Morimoto K., Bette M., Weihe E., Koprowski H., Dietzschold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J. Virol. 1998, 72:3711-3719.
17. Hooper D.C., Roy A., Kean R.B., Phares T.W., Barkhouse D.A. Therapeutic immune clearance of rabies virus from the CNS. Future Virol. 2011, 6:387-397.
18. Jackson A.C. Therapy of human rabies. Adv. Virus Res. 2011, 79:365-375.
19. Joseph J., Khan N.S., Rajoura O.P.A.M. Determinants of delay in initiating post-exposure prophylaxis for rabies prevention among animal bite cases: hospital based study. Vaccine 2013, 32:74-77.
20. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E.G., Shaw A., Zinsstag J., Meslin F.-X. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 2005, 83:360-368.
21. Li J., McGettigan J.P., Faber M., Schnell M.J., Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFκB signaling pathway. Vaccine 2008, 26:419-426.
22. Li J., Ertel A., Portocarrero C., Barkhouse D.A., Dietzschold B., Hooper D.C., Faber M. Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the central nervous system (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues. J. Virol. 2012, 86:3200-3210.
23. Liu X., Yang Y., Sun Z., Chen J., Ai J., Dun C., Fu Z.F., Niu X., Guo X. A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge. PLoS ONE 2014, 9:e87105.
24. Macpherson I., Stoker M. Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence. Virology 1962, 16:147-151.
25. Martinez L. Global infectious disease surveillance. Int. J. Infect. Dis. 2000, 4:222-228.
26. Patterson C.E., Lawrence D.M.P., Echols L.A., Rall G.F. Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent. J. Virol. 2002, 76:4497-4506.
27. Phares T.W., Kean R.B., Mikheeva T., Hooper D.C. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. 2006, 176:7666-7675.
28. Phares T.W., Fabis M.J., Brimer C.M., Kean R.B., Hooper D.C. A peroxynitrite-dependent pathway is responsible for blood-brain barrier permeability changes during a central nervous system inflammatory response: TNF-alpha is neither necessary nor sufficient. J. Immunol. 2007, 178:7334-7343.
29. Rafael J.A., Nitta Y., Peters J., Davies K.E. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. Mamm. Genome 2000, 11:725-728.
30. Rottenberg M., Kristensson K. Effects of interferon-γ on neuronal infections. Viral Immunol. 2002, 15:247-260.
31. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 1994, 13:4195-4203.
32. Schutsky K., Curtis D., Bongiorno E.K., Barkhouse D.A., Kean R.B., Dietzschold B., Hooper D.C., Faber M. Intramuscular inoculation of mice with the live-attenuated recombinant rabies virus TriGAS results in a transient infection of the draining lymph nodes and a robust, long-lasting protective immune response against rabies. J. Virol. 2013, 87:1834-1841.
33. Laboratory Techniques in Rabies, 1996, World Health Organization, World Health Organization, Geneva.
34. Willoughby R.E., Tieves K.S., Hoffman G.M., Ghanayem N.S., Amlie-Lefond C.M., Schwabe M.J., Chusid M.J., Rupprecht C.E. Survival after treatment of rabies with induction of coma. N. Engl. J. Med. 2005, 352:2508-2514.
35. Wu X., Franka R., Henderson H., Rupprecht C.E. Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. Vaccine 2011, 29:4195-4201.